These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 28895771)

  • 1. Platelet reactivity-adjusted antiplatelet therapy in patients with percutaneous coronary intervention: a meta-analysis of randomized controlled trials.
    Xing Z; Tang L; Zhu Z; Huang J; Peng X; Hu X
    Platelets; 2018 Sep; 29(6):589-595. PubMed ID: 28895771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The optimal discontinuation of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention with drug-eluting stents: A meta-analysis of randomized trials.
    Wang W; Liu J; Fang J; Liu Y; An T; Zou M; Cheng G
    Int J Cardiol; 2017 May; 235():73-86. PubMed ID: 28284499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
    Galli M; Benenati S; Capodanno D; Franchi F; Rollini F; D'Amario D; Porto I; Angiolillo DJ
    Lancet; 2021 Apr; 397(10283):1470-1483. PubMed ID: 33865495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis of randomized controlled trials comparing percutaneous coronary intervention with aspiration thrombectomy Vs. Conventional percutaneous coronary intervention during ST-segment elevation myocardial infarction.
    Dominguez AC; Bittl JA; El-Hayek G; Contreras E; Tamis-Holland JE
    Catheter Cardiovasc Interv; 2016 Jun; 87(7):1203-10. PubMed ID: 26699698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: systematic review and meta-analysis.
    Aradi D; Komócsi A; Price MJ; Cuisset T; Ari H; Hazarbasanov D; Trenk D; Sibbing D; Valgimigli M; Bonello L;
    Int J Cardiol; 2013 Sep; 167(5):2140-8. PubMed ID: 22704866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Meta-analysis on safety and efficacy of dual antiplatelet therapy combining with proton pump inhibitors for patients after percutaneous coronary intervention].
    Che QQ; Wu Q; Liang YB; Sun RM; Lyu QW; Ma JL; Hu H; Lin X; Xu GL; Sun SG; Zhang C; Wang QY; Yu J; Bai F
    Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Feb; 47(2):129-140. PubMed ID: 30818941
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety and Efficacy of Dual Versus Triple Antithrombotic Therapy in Patients Undergoing Percutaneous Coronary Intervention.
    Agarwal N; Jain A; Mahmoud AN; Bishnoi R; Golwala H; Karimi A; Mojadidi MK; Garg J; Gupta T; Patel NK; Wayangankar S; Anderson RD
    Am J Med; 2017 Nov; 130(11):1280-1289. PubMed ID: 28460853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotype-guided antiplatelet therapy compared with standard therapy for patients with acute coronary syndromes or undergoing percutaneous coronary intervention: A systematic review and meta-analysis.
    Wang X; Wang S; Yang J; Yu X; Liu L
    Thromb Res; 2020 Sep; 193():130-138. PubMed ID: 32559569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of short-term 1-3 months versus standard 12 months dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized clinical trials.
    Zhang WJ; Qiao X; Liang XY; Li Y; Yang RR; Wang ZL
    Platelets; 2021 Jul; 32(5):582-590. PubMed ID: 32627616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy and safety of CYP2C19 genotype-guided antiplatelet therapy compared with conventional antiplatelet therapy in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials.
    Lyu SQ; Yang YM; Zhu J; Wang J; Wu S; Zhang H; Shao XH; Ren JM
    Platelets; 2020 Nov; 31(8):971-980. PubMed ID: 32546030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefits of laboratory personalized antiplatelet therapy in patients undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials.
    Zhang Y; Zhang P; Li Z; Du J; Wang J; Tian X; Gao M; Hou Y
    Cardiol J; 2018; 25(1):128-141. PubMed ID: 29064534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three versus 12-month dual antiplatelet therapy duration in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials.
    Selvaraj V; Chatterjee S; Hirai T; Abbott JD; Bavishi C
    Catheter Cardiovasc Interv; 2022 Dec; 100(7):1151-1158. PubMed ID: 36326115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons.
    Chen Y; Zhang Y; Tang Y; Huang X; Xie Y
    Curr Med Res Opin; 2014 Jan; 30(1):37-49. PubMed ID: 24083626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What is the optimal approach to a non- culprit stenosis after ST-elevation myocardial infarction - Conservative therapy or upfront revascularization? An updated meta-analysis of randomized trials.
    Anantha Narayanan M; Reddy YN; Sundaram V; Reddy YN; Baskaran J; Agnihotri K; Badheka A; Patel N; Deshmukh A
    Int J Cardiol; 2016 Aug; 216():18-24. PubMed ID: 27135152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction.
    Nairooz R; Sardar P; Amin H; Swaminathan RV; Kim LK; Chatterjee S; Feldman DN
    Am J Cardiol; 2014 Jul; 114(2):250-9. PubMed ID: 24890986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual anti-platelet therapy following percutaneous coronary intervention in a population of patients with thrombocytopenia at baseline: a meta-analysis.
    Long M; Ye Z; Zheng J; Chen W; Li L
    BMC Pharmacol Toxicol; 2020 Apr; 21(1):31. PubMed ID: 32334636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prasugrel vs Ticagrelor for DAPT in Patients with ACS Undergoing PCI: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Al-Abdouh A; Barbarawi M; Abusnina W; Amr M; Zhao D; Savji N; Hasan RK; Michos ED
    Cardiovasc Revasc Med; 2020 Dec; 21(12):1613-1618. PubMed ID: 32513604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen).
    Park KW; Kang SH; Park JJ; Yang HM; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Chae IH; Kim HS
    JACC Cardiovasc Interv; 2013 Sep; 6(9):932-42. PubMed ID: 24050860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of single vs dual antiplatelet therapy in patients on anticoagulation undergoing percutaneous coronary intervention: A systematic review and meta-analysis.
    Atti V; Turagam MK; Garg J; Velagapudi P; Patel NJ; Basir MB; Mujer MT; Rayamajhi S; Abela GS; Koerber S; Gopinnathanair R; Lakkireddy D
    J Cardiovasc Electrophysiol; 2019 Nov; 30(11):2460-2472. PubMed ID: 31432607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensified Antiplatelet Treatment Reduces Major Cardiac Events in Patients with Clopidogrel Low Response: A Meta-analysis of Randomized Controlled Trials.
    Xu L; Hu XW; Zhang SH; Li JM; Zhu H; Xu K; Chen J; Li CJ
    Chin Med J (Engl); 2016 Apr; 129(8):984-91. PubMed ID: 27064045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.